ArticleWorld journal of diabetes2025
Postprandial C-peptide is more relevant to hemoglobin A1c levels and diabetic microvascular complications than fasting C-peptide in type 2 diabetes.
Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM), driven by insulin resistance and β cell dysfunction, necessitates reliable assessment of β cell function. C-peptide (CP) measurement, a stable marker of endogenous insulin secretion, is useful for this clinically as it avoids interference from exogenous insulin. While fasting CP (FCP) and postprandial CP (PCP), along with glucose-adjusted indices and ratios, such as FCP/fasting plasma glucose (FPG), 2 hours postprandial CP (2hCP)/postprandial blood glucose (PBG) and CP ratio, are used, their comparative efficacy in reflecting β cell function remains unclear. Hemoglobin A1c (HbA1c), a key glycemic control indicator, theoretically links β cell function to complications, but limited studies have explored the associations between diverse CP indices, HbA1c, and diabetic microvascular complications.
aimTo investigate the relationships between different CP indices and HbA1c as well as diabetic microvascular complications in T2DM.
methodsT2DM patients admitted to Department of Endocrinology at Beijing Hospital between July 1, 2021 and December 31, 2021 were included in the study. Clinical and laboratory data were collected, including CP levels, glucose levels, HbA1c levels and diabetic microvascular complications. Statistical analysis was performed using Statistical Package for the Social Sciences 24.0.
resultsA total of 453 patients were included in the final analysis. Adjusted by confounding factors, CP ratio and CP/blood glucose (BG) ratio were not relevant to HbA1c, but FCP, 2hCP, delta CP, FCP/FPG, 2hCP/PBG and delta CP/BG were still negatively correlated to HbA1c
conclusionThis study indicates that higher levels of CP indices suggest better glucose control and a lower prevalence of diabetic microvascular complications, and PCP indices, particularly 2hCP/PBG, were more relevant to HbA1c and diabetic microvascular complications than FCP indices. These results suggest CP-related indices could be useful biomarkers for diabetes management, warranting further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.